Shorted
Australian Clinical Labs logo
ACL
Health Care Equipment & Services

Australian Clinical Labs

Short interest
4.47%
−0.36 pp 30d
as of 8 Oct 2026
Reported shorts
8.3M
Shares on issue
186.519M

Australian Clinical Labs (ACL) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
14 Sept

Sarah Butler, Director of Australian Clinical Labs, Purchases 18,000 Shares in On-Market Transaction

Australian Clinical Labs Limited (ASX:ACL) announced that director Sarah Butler acquired 18,000 ordinary shares through an on-market transaction on 10 September 2026, at an average price of $2.77 per share, as detailed in a Change of Director's Interest Notice filed with the ASX. Key Points On 10 September 2026, director Sarah Butler purchased 18,000 ordinary shares via an on-market trade. The shares were bought at an average price of $2.77 each. The acquisition was made indirectly through Be...

Continue reading
Kalkine
Neutral
3 Sept

Is Australian Clinical Labs (ASX:ACL) Entering the Healthcare Stocks Spotlight?

Highlights Underlying profit grew even as group revenue eased slightly across the pathology and imaging businesses. Labour productivity and procurement savings more than offset funding cuts and rising wage costs. Management lifted the dividend while guiding toward further margin improvement in the coming year. Australian Clinical Labs Limited (ASX:ACL), the pathology and diagnostic imaging operator, reported wider profit margins for the year despite a modest revenue pullback, a result that st...

Continue reading
Kalkine
Neutral
16 Aug

Australian Clinical Labs (ASX:ACL): Why Are Margins Improving?

Highlights Australian Clinical Labs has reported stronger underlying profitability, with margin improvement emerging as a central feature of the latest full-year result. Operational efficiency, collection-centre optimisation and technology-led workflow improvements are becoming more important as pathology market growth remains measured. The next phase depends on maintaining service quality, strengthening cash conversion and converting productivity initiatives into repeatable earnings quality. ...

Continue reading
Kalkine
Neutral
24 July

Can ACL (ASX:ACL) Repair Smallcap Health Sentiment?

Highlights ACL is drawing attention as healthcare small caps are being weighed against tariff and margin concerns. Testing volumes, cost discipline and balance-sheet stability shape the current ASX read. Nanosonics adds peer context as smallcap stocks face a stricter market screen. ACL, a pathology and diagnostic services company, is being pulled into a sharper Australian market conversation as healthcare small caps are being weighed against tariff and margin concerns. Nanosonics (ASX:NAN), a ...

Continue reading
Kalkine
Neutral
20 July

Why Australian Clinical Labs (ASX:ACL), Hammer Metals (ASX:HMX) and Pacific Lime & Cement (ASX:PLA) Are Back on the Small-Cap Radar

Highlights Australian Clinical Labs (ASX:ACL) continues strengthening its healthcare services platform while advancing operational initiatives. Hammer Metals (ASX:HMX) remains in focus as exploration activities and corporate developments reshape investor attention. Pacific Lime & Cement (ASX:PLA) continues progressing strategic project development backed by leadership and operational initiatives. Australia's small-cap market continues to attract attention despite periods of broader market v...

Continue reading
Kalkine
Neutral
19 June

Why Australian Clinical Labs Is Back on the Small-Cap Radar

Highlights Australian Clinical Labs continues attracting attention due to its healthcare sector exposure and improving balance sheet position. Barton Gold remains focused on advancing exploration activities while maintaining a debt-free structure. Both companies highlight different opportunities emerging within Australia's small-cap market. Australian Clinical Labs and Barton Gold highlight opportunities across healthcare diagnostics and gold exploration within Australia’s growing small...

Continue reading